LISATA THERAPEUTICS, INC. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Lisata Therapeutics filed Form 8-K on 24 July 2026 reporting termination of a material definitive agreement (Item 1.02). The filing provides no specifics: no counterparty name, dollar amounts, contract terms, effective date of termination, or business rationale are disclosed in the header or structured data. The actual 8-K document text is not provided in this submission excerpt.
Why this rating
Without disclosed terms, cannot assess materiality. Agreement described as 'material' suggests potential business impact, but $23.6M market cap firm terminating contracts is routine. Lack of transparency is concerning but cannot quantify effect.
Extracted items
- 1.02 agreement termination
- 8.01 other event
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.